

1: Majumder MM, Silvennoinen R, Anttila P, Tamborero D, Eldfors S, Yadav B, Karjalainen R, Kuusanmäki H, Lievonen J, Parsons A, Suvela M, Jantunen E, Porkka K, Heckman CA. Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. *Oncotarget*. 2017 May 5. doi: 10.18632/oncotarget.17630. [Epub ahead of print] PubMed PMID: 28525891.

2: Varmavuo V, Silvennoinen R, Anttila P, Säily M, Sankelo M, Putkonen M, Ahonen J, Mahlamäki E, Mäntymaa P, Savolainen ER, Remes K, Jantunen E. Cost analysis of a randomized stem cell mobilization study in multiple myeloma. *Ann Hematol*. 2016 Oct;95(10):1653-9. doi: 10.1007/s00277-016-2772-1. Epub 2016 Aug 3. PubMed PMID: 27485453.

3: Valtola J, Silvennoinen R, Ropponen A, Siitonen T, Säily M, Sankelo M, Terävä V, Putkonen M, Kuittinen T, Pelkonen J, Mäntymaa P, Remes K, Varmavuo V, Jantunen E. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison. *Transfusion*. 2016 Jun;56(6):1394-401. doi: 10.1111/trf.13574. Epub 2016 Apr 4. PubMed PMID: 27041692.

4: Lindström V, Aittoniemi J, Lyytikäinen O, Klemets P, Ollgren J, Silvennoinen R, Nuorti JP, Sinisalo M. Invasive pneumococcal disease in patients with haematological malignancies before routine use of conjugate vaccines in Finland. *Infect Dis (Lond)*. 2016;48(5):399-402. doi: 10.3109/23744235.2015.1115894. Epub 2015 Dec 4. PubMed PMID: 26635103.

5: Silvennoinen R, Anttila P, Säily M, Lundan T, Heiskanen J, Siitonen TM, Kakko S, Putkonen M, Ollikainen H, Terävä V, Kutila A, Launonen K, Räsänen A, Sikiö A, Suominen M, Bazia P, Kananen K, Selander T, Kuittinen T, Remes K, Jantunen E. A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma. *Bone Marrow Transplant*. 2016 Mar;51(3):372-6. doi: 10.1038/bmt.2015.236. Epub 2015 Oct 5. PubMed PMID: 26437056; PubMed Central PMCID: PMC4777887.

6: Valtola J, Varmavuo V, Ropponen A, Nihtinen A, Partanen A, Vasala K, Lehtonen P, Penttilä K, Pyörälä M, Kuittinen T, Silvennoinen R, Nousiainen T, Pelkonen J, Mäntymaa P, Jantunen E. Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison. *Transfusion*. 2015 Oct;55(10):2358-68. doi: 10.1111/trf.13170. Epub 2015 May 28. PubMed PMID: 26018461.

7: Grövdal M, Nahi H, Gahrton G, Liwing J, Waage A, Abildgaard N, Pedersen PT, Hammerstrøm J, Laaksonen A, Bazia P, Terava V, Ollikainen H, Silvennoinen R, Putkonen M, Anttila P, Porkka K, Remes K. Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. *Bone Marrow Transplant*. 2015 Jun;50(6):808-12. doi: 10.1038/bmt.2015.39. Epub 2015 Apr 13. PubMed PMID: 25867654.

8: Silvennoinen R, Lundan T, Kairisto V, Pelliniemi TT, Putkonen M, Anttila P, Huotari V, Mäntymaa P, Siitonen S, Uotila L, Penttilä TL, Juvonen V, Selander T, Remes K. Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma. *Blood Cancer J*. 2014 Oct 10;4:e250. doi: 10.1038/bcj.2014.69. PubMed PMID: 25303369; PubMed Central PMCID: PMC4220647.

9: Oksi J, Rantala S, Kilpinen S, Silvennoinen R, Vornanen M, Veikkolainen V, Eerola E, Pulliainen AT. Cat scratch disease caused by Bartonella grahamii in an immunocompromised patient. *J Clin Microbiol*. 2013 Aug;51(8):2781-4. doi: 10.1128/JCM.00910-13. Epub 2013 Jun 5. PubMed PMID: 23740723; PubMed Central PMCID: PMC3719609.

10: Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A, Guldbrandsen N, Haukås E, Carlson K, Kvam AK, Nahi H, Lindås R, Andersen NF, Turesson I, Waage A, Westin J; Nordic Myeloma Study Group.. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. *Blood*. 2013 Jun 6;121(23):4647-54. doi: 10.1182/blood-2012-11-464503. Epub 2013 Apr 24. PubMed PMID: 23616624; PubMed Central PMCID: PMC3674665.

11: Silvennoinen R, Kairisto V, Pelliniemi TT, Putkonen M, Anttila P, Säily M, Sikiö A, Opas J, Penttilä K, Kuittinen T, Honkanen T, Lundán T, Juvonen V, Luukkaala T, Remes K. Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients. *Br J Haematol*. 2013 Feb;160(4):561-4. doi: 10.1111/bjh.12139. Epub 2012 Dec 4. PubMed PMID: 23206270.

12: Varmavuo V, Mäntymaa P, Silvennoinen R, Nousiainen T, Kuittinen T, Jantunen E. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. *Transfusion*. 2013 May;53(5):1024-32. doi: 10.1111/j.1537-2995.2012.03848.x. Epub 2012 Aug 15. PubMed PMID: 22897584.

13: Sinisalo M, Silvennoinen R, Wirta O. High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy. *Am J Hematol*. 2012 Jun;87(6):640. doi: 10.1002/ajh.23189. Epub 2012 Mar 31. PubMed PMID: 22473521.

14: Syrjälä H, Ohtonen P, Kinnunen U, Rätty R, Elonen E, Nousiainen T, Jantunen E, Remes K, Itälä-Remes M, Silvennoinen R, Koistinen P; Finnish Leukemia Group.. Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. *Eur J Clin Microbiol Infect Dis*. 2010 Oct;29(10):1211-8. doi: 10.1007/s10096-010-0984-1. Epub 2010 Jun 17. PubMed PMID: 20556469.

15: Usvasalo A, Rätty R, Knuutila S, Vettenranta K, Harila-Saari A, Jantunen E, Kauppila M, Koistinen P, Parto K, Riikonen P, Salmi TT, Silvennoinen R, Elonen E, Saarinen-Pihkala UM. Acute lymphoblastic leukemia in adolescents and young adults in Finland. *Haematologica*. 2008 Aug;93(8):1161-8. doi: 10.3324/haematol.12466. Epub 2008 Jun 12. PubMed PMID: 18556413.

16: Jantunen E, Itälä M, Siitonen T, Kuittinen T, Heiskanen J, Koivunen E, Juvonen E, Silvennoinen R, Nousiainen T, Koistinen P, Volin L, Remes K. Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis. *Bone Marrow Transplant*. 2008 Feb;41(3):239-44. Epub 2007 Oct 29. PubMed PMID: 17968327.

17: Koistinen P, Rätty R, Itälä M, Jantunen E, Koivunen E, Nousiainen T, Pelliniemi TT, Remes K, Ruutu T, Savolainen ER, Siitonen T, Silvennoinen R, Volin L, Elonen E; Finnish Leukaemia Group.. Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group. *Eur J Haematol*. 2007

18: Ruutu T, Koivunen E, Nousiainen T, Pelliniemi TT, Almqvist A, Anttila P, Jantunen E, Koistinen P, Koponen A, Mikkola M, Oksanen K, Pulli T, Remes K, Sarkkinen R, Silvennoinen R, Timonen T, Vanhatalo S, Elonen E; Finnish Leukaemia Group.. Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle. *Eur J Haematol.* 2004 Jan;72(1):38-44. PubMed PMID: 14962261.

19: Silvennoinen R, Malminiemi K, Malminiemi O, Seppälä E, Vilpo J. Pharmacokinetics of chlorambucil in patients with chronic lymphocytic leukaemia: comparison of different days, cycles and doses. *Pharmacol Toxicol.* 2000 Nov;87(5):223-8. PubMed PMID: 11129502.

20: Hovinen J, Silvennoinen R, Vilpo J. Detoxification of an alkylating drug, N,N-bis(2-chloroethyl)-p-aminophenylbutyric acid (chlorambucil), in human gastric juice and saliva. *Chem Res Toxicol.* 1998 Feb;11(2):91-3. PubMed PMID: 9511899.